Shanghai Zhongshan Hospital Saves 17-Year-Old Cancer Patient with 99% Coronary Artery Blockage
When Cancer Treatment Threatens the Heart
Seventeen-year-old Xiao Zhang had been fighting cancer for four years. Diagnosed with mediastinal lymphoepithelioma-like carcinoma, she had endured surgery, chemotherapy, radiation, targeted therapy, and immunotherapy. Her body was already fragile when an even more dangerous crisis struck — her heart.
The Discovery
In January 2026, Xiao Zhang was admitted to Zhongshan Hospital (affiliated with Fudan University, Shanghai) with rapidly worsening chest tightness and shortness of breath after minimal activity.
The test results were alarming:
- Cardiac troponin T: Markedly elevated — indicating active heart muscle damage
- Heart function markers: Severely abnormal
- ECG: Widespread signs of serious myocardial injury
- Coronary CT angiography: The left main coronary artery — the heart's "main pipeline" — was over 99% blocked, nearly completely occluded
Her heart could stop at any moment.
The Multidisciplinary Response
Professor Cheng Leilei, head of Zhongshan Hospital's Cardio-Oncology subspecialty, immediately assembled an emergency multidisciplinary team including:
- Cardiology — Coronary intervention specialists
- Oncology — Immunotherapy management
- Rheumatology/Immunology — Ruling out immune-mediated myocarditis
- Radiology — Advanced cardiac imaging
After excluding immune-mediated myocarditis, the team identified the cause: long-term immunotherapy had accelerated severe coronary artery disease — a known but serious complication of immune checkpoint inhibitors.
The High-Risk Intervention
Under the guidance of Academician Ge Junbo (Chinese Academy of Sciences member and Director of Cardiology at Zhongshan Hospital), Dr. Lu Hao performed the coronary intervention.
The angiography revealed a situation worse than expected:
| Artery | Blockage |
|---|---|
| Left main coronary artery | 95% stenosis |
| Left anterior descending (LAD) | Complete occlusion (100%) |
| Left circumflex artery (LCx) | 90% stenosis |
The heart's blood supply was barely maintained through tiny collateral vessels. For a 17-year-old with advanced cancer and a severely weakened body, this intervention was extraordinarily high-risk.
The critical challenge: the guidewire had to navigate through hardened, calcified, nearly completely blocked vessel segments under intravascular ultrasound guidance. Any slight deviation could perforate the vessel wall or create a dissection — with potentially fatal consequences.
With precision skill, Dr. Lu successfully positioned the guidewire and deployed drug-eluting stents, reopening the blocked vessels. Fresh blood flowed into the oxygen-starved heart muscle for the first time in weeks.
The Outcome
Post-procedure, Xiao Zhang's recovery was remarkable:
- Chest tightness and breathing difficulty resolved rapidly
- Cardiac biomarkers normalized progressively
- Heart function began recovering steadily
She was discharged and, along with her family, expressed deep gratitude to the cardio-oncology team.
The Growing Field of Cardio-Oncology
This case highlights an increasingly important medical subspecialty: cardio-oncology — the intersection of cancer treatment and cardiovascular health.
Immune checkpoint inhibitors (ICIs) like PD-1/PD-L1 antibodies have revolutionized cancer treatment, but they carry cardiovascular risks:
- Myocarditis — Inflammation of the heart muscle (rare but potentially fatal)
- Accelerated atherosclerosis — Rapid buildup of plaque in coronary arteries
- Arrhythmias — Irregular heart rhythms
- Pericarditis — Inflammation of the heart's outer lining
Expert recommendation: All patients receiving immunotherapy should have baseline cardiac evaluation (ECG, echocardiogram, cardiac enzymes) and regular monitoring, especially during the first 3 months of treatment. Any symptoms of chest tightness, shortness of breath, palpitations, or fatigue should prompt immediate evaluation.
Why This Case Demonstrates China's Medical Strength
This case showcases several advantages of China's top-tier hospitals:
- World-class multidisciplinary collaboration — Cardiology, oncology, immunology, and imaging working together seamlessly
- Cutting-edge subspecialties — Cardio-oncology is an emerging field, and Zhongshan Hospital is a leader
- Immediate access — No months-long waiting list; emergency intervention was performed promptly
- Top-tier interventional skills — Academician-level guidance for the most complex cases
About Zhongshan Hospital
- Fudan University-affiliated — One of China's top 5 hospitals
- Cardiology department led by Academician Ge Junbo, a globally recognized interventional cardiologist
- Pioneer in structural heart disease and complex coronary interventions in Asia
- Located in central Shanghai with dedicated international patient services
Need cardiac care or a second opinion from China's top cardiologists? Start with a free consultation →